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Background: A new sensitive colorimetric determination of nifedipine has been developed following azo dye
formation with 4-carboxyl-2,6-dinitrobenzenediazonium ion (CDNBD). Judging from the various generic brands
currently now available, this research was conceived as a means of developing an alternative cost-effective and
readily adaptable method for the assay of nifedipine in tablets and for which official high performance liquid
chromatographic technique may not be readily available.
Results: Nifedipine was reduced with Zn/HCl reduction system and then the diazo coupling reaction was carried out
with the CDNBD reagent to generate a new azo adduct with optimal wavelength at 470 nm representing a
bathochromic shift relative to nifedipine, reduced nifedipine and CDNBD reagent. Optimal temperature and time for
coupling were selected as 50 oC and 15 minutes. A linear response was observed over 2.9 -14.5 µg/mL of nifedipine
with a correlation coefficient of 0.9985 and the drug combined with CDNBD at a stoichiometric ratio of 2:1. The
method has limits of detection and quantitation of 0.1344 µg mL-1 and 0.4074 µg mL-1 respectively. The Sandell’s
sensitivity obtained is 4.673 ng/cm2 and the method was reproducible over a three day assessment. Intra- and inter-day
accuracies (in terms of errors) were of the order -0.008 to 3.22 % while precisions were generally less than 3.1 % (RSD).
Conclusions: The developed spectrophotometric method is of equivalent accuracy (p> 0.05) with USP 2007 HPLC
method. It has the advantages of speed, simplicity, sensitivity and more affordable instrumentation and could find
application as a rapid and sensitive analytical method for nifedipine. It is the first described method by azo dye
derivatization for the analysis of nifedipine in bulk samples and dosage forms.
Keywords: Nifedipine tablets, 4-carboxyl-2, 6-dinitrobenzene diazonium ion, Azo dye derivatization, Colorimetric analysisBackground
Nifedipine, chemically dimethyl-2, 6-dimethyl-4-(2-
nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate,
has an empirical formula of C17H18N2O6. It is com-
monly available in capsule and extended-release tablet
dosage forms. Nifedipine, which occurs as a yellow crys-
talline powder, has a melting point of 172°C to 174°C
and is practically insoluble in water, sparingly soluble in
dehydrated alcohol and freely soluble in acetone [1-3].
When exposed to daylight or to certain wavelengths of
artificial light, it is converted to a nitrosophenylpyridine
derivative, and exposure to ultraviolet light leads to the
formation of the same derivative [1]. The drug is official* Correspondence: jireade@yahoo.com
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any medium, provided the original work is pin the United States Pharmacopoeia (USP) [4], which
recommends high performance liquid chromatography
(HPLC) for its assay (both the pure drug and its dosage
forms), and in the BP [3], which recommends redox ti-
tration using cerium sulphate and HPLC for the assay
of the drug and its dosage forms, respectively.
Nifedipine, the prototypical 1,4-dihydropyridine, is a
calcium channel blocker with peripheral and coronary
vasodilator activity. It is used in the management of hyper-
tension, angina and some other cardiovascular disorders. Its
uses result primarily in vasodilatation, with reduced periph-
eral resistance, blood pressure, and afterload; increased cor-
onary blood flow; and a reflex increase in heart rate. This in
turn results in an increase in myocardial oxygen supply and
cardiac output. It acts by inhibiting the transmembrane in-
flux of calcium into cardiac and vascular smooth muscleis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0),which permits unrestricted use, distribution, and reproduction in
roperly cited.
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from the gastrointestinal tract but undergoes extensive
hepatic first-pass metabolism. Bioavailability of oral capsules
is between 45% and 75% but is lower for longer-acting for-
mulations. Peak blood concentrations were reported to
occur 30 min after oral doses of capsules. It is about 92% to
98% bound to plasma proteins and is distributed into breast
milk. It is extensively metabolised in the liver, and 70% to
80% of a dose is excreted in the urine almost entirely as
inactive metabolites. The half-life is about 2 h after intra-
venous doses or oral capsules [1].
Detailed survey of literature for nifedipine revealed several
methods that have been reported for the assay of nifedipine
either alone or in combined form in drug formulations.
These analytical techniques include UV-Visible (Vis) spec-
trophotometry [5-20], HPLC [21-28], high performance
thin layer chromatography [29], micellar electrokinetic
chromatography [30], electroanalytical methods [31-33],
flow injection analysis [34] and mass spectrometry [35].
Nifedipine alone has been estimated by second derivative
UV spectrophotometry [8], whereas first derivative UV
spectrophotometry was utilised for its assay in combined
dosage forms [9,10]. Two kinetic spectrophotometric
methods have been reported: One is based on the oxi-
dation of the drug with KMnO4 at neutral pH [11], and
the other method is based on the reduction of iron(III)
by the drug and subsequent interaction of iron(II) with
ferricyanide to form Prussian blue [12]. Some other
spectrophotometric methods involve a reduction of the
nitro group of nifedipine with Zn/NH4Cl and Zn/HCl
to hydroxylamino and primary aromatic amino derivatives,
respectively. The hydroxylamino derivative was reacted
with 4-(methylamino) phenol and potassium dichromate
[13], while the primary aromatic amino derivative formed
Schiff's bases with 3,4,5-trimethoxybenzaldehyde [14] and
4-dimethylaminobenzaldehyde [15]. Determinations of the
drug in pharmaceutical preparations via extractive spectro-
photometric methods have also been reported [7,16].
Other reported methods include the following: one involv-
ing a reaction of the nitro group of the drug with potas-
sium hydroxide in dimethyl sulphoxide [17], the oxidation
of the drug with ammonium molybdate [17], the formation
of blue-coloured complex with Folin Ciocalteau reagent
[18] and another based on the formation of a charge trans-
fer complex with chloranil [19]. Recently, Revathi et al.
reported a spectroscopic method based on hydrotropic
solubilisation in which the determination of nifedipine in
tablet formulations was done using 40% sodium salicylate
solution [20]. Majority of these methods suffer from the
disadvantage of extensive extraction procedures, long ana-
lytical time and high calibration range.
In continuation of our previous efforts in the analysis of
organic compounds of pharmaceutical importance
through azo dye chemical derivatization with 4-carboxyl-2,6-dinitrobenzene diazonium (CDNBD) ion [36-44], we
report in this paper a new simple, accurate and precise
colorimetric method for the assay of nifedipine in bulk
samples and tablet dosage forms.
Methods
Preparation of reduced nifedipine stock solution
A quantity of nifedipine CRS crystals (11.0 mg) was
weighed and dissolved in 1 mL of glacial acetic acid in a
20-mL beaker. This was warmed gently to ensure
complete dissolution. Two millilitres of concentrated
HCl was added followed by 400 mg of Zn dust. The
whole content was allowed to stand for 5 min. The solu-
tion was then filtered through a cotton wool plug into a
10-mL volumetric flask and made up to volume by adding
fresh glacial acetic acid rinsing the filter aid in the process.
This gave a 1 mg/mL of reduced nifedipine (RN) solution.
A stock solution of 100 μg/mL was thereafter made from
this and kept in a wrapped sample vial.
Preparation of CDNBD solution
The reagent solution of CDNBD ion was prepared in
concentrated sulphuric acid following diazotization of 4-
amino-3,5-dinitrobenzoic acid with sodium nitrite as
previously reported [45].
Selection of analytical wavelength
A 0.1-mL RN stock solution was added into a test tube
containing 0.5 mL of CDNBD solution. The mixture was
vortex mixed for 10 s, and the reaction tube was placed
in a thermostated water bath maintained at 50°C for
15 min. The reaction mixture was thereafter placed in an
ice bath; 2 mL of ice-cold distilled water was added and
made up to 5 mL with acetonitrile. The formation of the
azo adduct was monitored by normal-phase thin layer
chromatography (TLC) using ethyl acetate-methanol
mixture (9:1 and 8:2). The absorption spectrum of the
new orange-coloured adduct was determined against
CDNBD, nifedipine and RN blanks, using the UV–vis
spectrophotometer. The analytical wavelength (λmax) was
then determined by inspection of the overlaid spectra.
The wavelength where the difference in absorptivity is
maximal was selected as the analytical wavelength.
Optimisation studies
Temperature and time were optimised using the
method of steepest ascent. A 0.1 mL of the RN stock
solution was coupled with 0.5 mL of CDNBD in a test
tube, and the reaction mixture was mixed using a vor-
tex mixer. The sample tubes were incubated at 30°C
and 50°C for 5 and 20 min. Similar experiments were car-
ried out at 60°C and 80°C. At the end of each time interval,
the reaction mixture was placed in an ice bath, and the re-
action was terminated by adding 2 mL of ice-cold distilled
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sorbance readings of the azo adduct were taken at 470 nm
on the digital colorimeter. Each determination was done
in duplicate.
The optimal reaction time was determined by study-
ing the effect of varied time allowed for coupling to
take place at 50°C between RN and CDNBD at 5, 10,
15, 20 and 30 min. A 0.1 mL of RN stock solution was
added to 0.5 mL of the reagent in test tubes. The azo
adduct formed was processed as described above. The
optimal reaction time was taken as the time corre-
sponding to maximal absorbance of the samples. Each
determination was done in duplicate.
The effect of the diluting solvent on coupling reaction
was investigated using acetonitrile, ethanol, methanol
and 1-propanol. In each case, the reaction mixture was
terminated by adding 2 mL of ice-cold distilled water
and making up to 5 mL with the respective solvents. Ab-
sorbance readings were taken at 470 nm.
Determination of stoichiometric ratio for the formation of
azo dye
Aliquots of CDNBD reagent, 0, 0.2, 0.25, 0.33, 0.5, 0.67,
0.75, 0.8 and 1.0 mL, were added respectively into nine
test tubes. Each tube was in turn made up to 1.0 mL
with the drug stock solution. The mixture was vortex
mixed for 10 s followed by incubation at 50°C for
15 min. Afterwards, the reaction was terminated by adding
2 mL of ice-cold distilled water and making up to 5 mL
with acetonitrile. A series of blank determinations were
carried out in which the volume of the RN stock solution
was replaced with glacial acetic acid. The absorbance was
measured at 470 nm against the blank, and values
obtained were plotted against mole fraction of the reagent
solution. Each determination was carried out in duplicate.
Validation studies
The calibration curve for the azo adduct was prepared
using a concentration range of 0 to 14.5 μg/mL from
the stock of RN solution in glacial acetic acid. To
seven test tubes, each containing 0.67 mL of CDNBD
reagent solution, 0, 0.05, 0.075, 0.1, 0.15, 0.2 and
0.25 mL corresponding to 0, 2.88, 4.35, 5.8, 8.7, 11.6
and 14.5 μg/mL of RN stock solution were added re-
spectively. The mixture was vortex mixed for 10 s and
incubated at 50°C for 15 min. For each sample, the azo
adduct formed was processed as described above; the
absorbance reading was recorded at 470 nm. Calibration
curves were prepared everyday for 3 days, and the average
absorbance values were used in constructing the working
calibration curve. The regression line equation and correl-
ation coefficient were obtained from the calibration curve.
Accuracy and precision were determined through recov-
ery studies. These were determined using quadruplicatesamples at three concentration levels of 4.35, 8.7 and
11.6 μg/mL on three successive days. The volumes of RN
solution corresponding to these concentrations were mea-
sured, i.e. 0.075, 0.15 and 0.25 mL. Each volume was added
into test tubes containing 0.67 mL of CDNBD reagent so-
lution. The reaction mixture was vortex mixed for 10 s
and incubated at 50°C for 15 min. The azo adduct formed
was processed as described above, and the absorbance
reading was taken at 470 nm using acetonitrile as blank
solvent. This was done four times for each volume. A 3-
day recovery study was done, and the accuracy and preci-
sion were determined from the regression equation.
Application to tablet dosage form analysis
Six brands of nifedipine extended-release tablets (20 mg)
were analysed using the new colorimetric method devel-
oped in this study. Uniformity of weight test was carried
out on all the brands using 10 tablets.
The assay of active ingredients for the brands was
determined based on the new and official methods. For
the assay of the six brands of nifedipine tablets, six
different analyte stock solutions (A to F) of the same
concentration were prepared. Based on uniformity of
weight test, 105 mg of FrapineW (Medrel Pharmaceutical
Ltd., Mumbai, India), 113 mg of Nifedin DexcelW (Dexcel
Ltd., Hamilton, New Zealand), 47 mg of NifegemW
(Gemini Pharmaceuticals Ltd., Commack, NY, USA),
46 mg of NifecardW (Salutas Pharma GmbH, Barleben,
Germany), 45 mg of MedipineW (Cipla Ltd., Mumbai,
India) and 75 mg of Nife-DW (Lincoln Pharmaceuticals
Ltd., Ahmedabad, India) powdered tablets each corre-
sponding to 11 mg of nifedipine were weighed and dis-
persed in 1.0 mL of glacial acetic acid in a 20-mL beaker.
This was warmed gently to aid dissolution of the active
ingredient. Two millilitres of concentrated HCl was
added followed by 400 mg of Zn dust. The whole con-
tent was allowed to stand for 5 min. The solution was
then filtered through a cotton wool plug into a 10-mL
volumetric flask and made up to volume by adding fresh
glacial acetic acid rinsing the filter aid in the process.
This gave a 1 mg/mL of RN solution. An analyte stock
solution of 100 μg/mL was thereafter made from this
and kept in a wrapped sample vial.
From each analyte stock solution (A to F), 0.15 mL was
transferred into six tubes in turn containing 0.67 mL of
CDNBD reagent solution. The mixture was vortex mixed
for 10 s and incubated at 50°C for 15 min. Afterwards, the
tubes were transferred into an ice bath; 2 mL of ice-cold
distilled water was added and made up to 5 mL with
acetonitrile. The absorbance readings of the azo adduct
were measured at 470 nm on the colorimeter.
The analysis of the tablet samples was also repeated
using the USP [3] HPLC procedures, which were
adopted as the official procedure.
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A 0.15-mL quantity of the stock corresponding to 8.7 μg/
mL of RN was spiked into tablet excipients containing
5 mg each of lactose, starch, gelatine, magnesium stearate,
talc and a mixture of the five excipients. Coupling and pro-
cessing of the azo adduct that was formed were carried out
as described above.
Results and discussion
Chemistry of the reaction
The diazo coupling reaction between CDNBD reagent
solution and RN gave an instant orange-yellow colour
that became deeper with time. The colour formation
indicates the formation of an azo dye (Scheme 1). This
colour is distinct from the colourless solution of RN inScheme 1 Proposed coupling pattern between reduced nifedipine anglacial acetic acid. TLC analysis revealed the formation
of a new compound. As shown in Scheme 1, the nitro
group on nifedipine was reduced to an amino group by
Zn/HCl. This is accompanied by the cleavage of the two
ester linkages (to give carboxylic acids) since the reaction
is taking place in an acidic medium at a slightly elevated
temperature. Another possible reaction occurring in the
medium is the aromatization of the dihydropyridine
moiety to pyridine. This is so because aromatization is
accomplished most easily in dihydropyridines and much
more when the ring is fused to an aromatic ring [46] as
is the case in nifedipine. The end result of all these reac-
tions is the formation of new species which on coupling
with CDNBD elongates the chromophoric conjugation,
leading to absorption of light in the visible region.d CDNBD.
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The absorption spectrum of nifedipine shows two absorp-
tion maxima at 230 nm and 333 nm, while RN shows two
absorption maxima at 224 nm and 310 nm. The spectrum
of the adduct shows two maxima at 230 nm and 270 nm
in the UV region and a new prominent peak at 470 nm,
denoting extension of conjugation. The blank reagent exhi-
bits absorption maxima at 258 nm, 333 nm and 423 nm.
The overlaid absorption spectra of nifedipine, RN, the azo
adduct and CDNBD reagent are presented in Figure 1. The
spectrum of the azo adduct shows a bathochromic shift
with respect to both the nifedipine and RN due to chromo-
phoric elongation caused by the new azo linkage. A hyper-
chromic shift observed in the spectrum of the azo adduct
when compared with CDNBD is expected also due to a
higher number of chromophores. The peak at 470 nm was
selected as the analytical wavelength because at this wave-
length, the difference in absorptivity between the blank re-
agent and the azo adduct was maximal.
Effect of diluting solvents
In studying the effect of diluting solvents using acetonitrile,
ethanol, methanol and 1-propanol, the highest absorbance
value was obtained with acetonitrile as the diluting solvent.
This might be so because the alcohols are protic solvents
promoting the formation of hydrogen bonding which in-
variably results in lower absorbance values due probably to
reduction in the propensity of azo dye formation by inter-
action with the amino group on the residual nifedipine mol-
ecule to generate NH3
+ which reduces the directing effects
of the group for the in-coming CDNBD molecule. For
acetonitrile, however, which is a polar aprotic solvent, itsFigure 1 Absorption spectra of nifedipine, RN, CDNBD and the
azo adduct formed between RN and CDNBD.inability to promote hydrogen bonding formation probably
results in the absorbance value being higher.
Optimisation studies
The first set of optimisation studies conducted was the de-
termination of the optimum temperature and time required
for the diazo coupling reaction between RN and CDNBD.
As shown in Figure 2, there was an increase inabsorbance
from 30°C to 60°C at both 5 and 20 min incubation period.
Although there was no significant difference in the absorb-
ance produced at 50°C and 60°C (i.e. 0.390 and 0.398 at
5 min; 0.395 and 0.4 at 20 min, respectively). Thus, 50°C
was selected as the coupling reaction temperature. After 60°
C, there was a decrease in absorbance. This reduction in ab-
sorbance at a temperature greater than 60°C could have
been due to thermal decomposition of the azo adduct
formed as previously noted in the utilisation of CDNBD as
a derivatizing reagent. A temperature of 50°C was selected
as being the optimum temperature for the reaction of RN
with CDNBD. Optimisation of reaction time was thereafter
carried out at 50°C. It was observed as shown in Figure 3
that the absorbance value peaked at 15 min, and thereafter,
absorbance values reduced with increase in time up to a
final decline at 30 min. Thermal decomposition of the azo
adduct may also be responsible as observed for the assess-
ment of optimal temperature. Thus, optimal conditions for
the coupling reaction were established at 50°C and 15 min.
Reaction stoichiometry
The optimal ratio for the formation of the azo adduct was
investigated using Job's method of continuous variation.
The result is presented in Figure 4. The highest possibleFigure 2 Optimization of coupling reaction temperature.
Figure 3 Optimization of coupling reaction time at 50°C.
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for the reagent solution, and the absorbance was found to
decrease at lower or higher mole fractions. This shows that
CDNBD and RN react in a 2:1 stoichiometric ratio. From
our previous work, it has been discovered that higher di-
azonium concentration is necessary for azo dye formation
[44]. It is therefore proposed that a single adduct is gener-
ated, but a higher reagent ratio is required for optimal de-
tector response. Any of the reaction steps taking place in
situ may have also required a higher mole fraction of the
CDNBD reagent, leading subsequently to the 2:1 reagent to
drug ratio.Figure 4 Stoichiometric ratio determination for the formation
of azo adduct between reduced nifedipine and CDNBD.Validation of the new colorimetric method
For validation studies, calibration lines were prepared
on three successive days, and the average absorbance
readings were used to describe the linear regression line
for the assay of nifedipine by the CDNBD method. The
assays of nifedipine were linear over the range of 2.9 to
14.5 μg/mL of nifedipine with a linear regression of
Y = 0.0214X+ 0.0061 and a correlation coefficient of
0.9985. The 95% confidence intervals for the slope and
intercept are in the range of 0.0214±9.86×10−4 and
0.0061±5.09×10−4, translating to 4.6% and 8.3%, respect-
ively. The limits of detection (LOD) and quantitation
(LOQ) were estimated as stipulated by the ICH guidelines
[47] using the expressions below:
LOD ¼ 3:3σ
s
and LOQ ¼ 10σ
s
where σ is the standard deviation of the blank signals, and
s is the slope of the calibration graph. The LOD and LOQ
values obtained respectively are 0.1344 μg mL−1 and
0.4074 μg mL−1. The Sandell sensitivity obtained is
4.673 ng/cm2. The various analytical and validation para-
meters are summarised in Table 1. The values obtained for
the LOD, LOQ and Sandell's sensitivity point to the highly
sensitive nature of this new colorimetric method for the
determination of nifedipine in bulk and tablet dosage
forms. It is one of the recently reported methods for ni-
fedipine with such a high sensitivity and makes it hold a
promise for the quantitative determination of this import-
ant cardiovascular agent.
Accuracy and precision were estimated over 3 days by
recovery studies. The intra- and inter-day data obtained
are presented in Tables 2 and 3, respectively. Accuracy,
as estimated by relative errors, ranged from 1.15% toTable 1 Analytical and validation parameters for the
assay of nifedipine using CDNBD
Parameter Value
Maximum wavelength of absorption (λmax) 470 nm
Beer's law limits (μg mL−1) 2.9 to 14.5
Limit of detection (μg mL−1) 0.1344
Limit of quantitation (μg mL−1) 0.4074
Molar absorptivity (Mol−1 cm2) (1.929 ± 0.271) × 103





95% confidence interval of slope, β 9.87 × 10−4
Intercept, a 0.0061
95% confidence interval of Intercept, α 5.09 × 10−4
Correlation coefficient, r 0.9985
aY = bX + a, where Y is the absorbance for concentration X μg mL−1.
Table 4 Assay of nifedipine in tablets using the CDNBD
and official HPLC methods











20 Frapine 102.65 ± 3.10 97.35 ± 1.28 0.18 0.06
20 Nifedin 101.30 ± 2.69 98.98 ± 1.07 0.16 0.12
20 Nifegem 101.30 ± 2.69 101.91 ± 0.58 0.03 0.71
20 Nifecard 98.62 ± 2.69 97.18 ± 3.38 0.72 0.64
20 Medipine 97.28 ± 3.10 96.96 ± 2.17 0.57 0.90
20 Nife-D 95.93 ± 2.69 97.21 ± 1.85 0.55 0.42












Nifedipine 4.35 4.489 103.19 0.048 3.218
8.7 8.930 102.64 3.032 2.644
11.6 11.734 101.15 2.299 1.151
n= 4 for each concentration. RSD, relative standard deviation.
Aderibigbe et al. International Journal of Industrial Chemistry 2012, 3:5 Page 7 of 8
http://www.industchem.com/content/3/1/53.22% for intra-day assessment and −0.008% to 3.22% for
inter-day assessment. The precision was generally good
with a relative standard deviation of less than 3.1% for
both intra- and inter-day assessment. The percentage re-
coveries for all analyte levels both at intra- and inter-day
assessment were all close to 100%, justifying the suitability
of this new colorimetric method.
Interference studies
The influence of commonly utilised excipients on the re-
covery of nifedipine from the reaction medium was stud-
ied in the presence of common excipients. The recoveries
of nifedipine are as follows: starch, 103.98± 0.23%; lactose,
102.64± 0.27%; magnesium stearate, 101.30± 0.23%; gel-
atin, 103.98± 0.23; talc, 102.64± 0.27%; and a mixture of
these excipients, 103.98± 0.23% (n=6 in all determina-
tions). With the good recoveries obtained, it implies that
the method is free from undue interference by the com-
monly utilised tablet excipients.
Application to analysis of tablets
The new method was applied to the assay of nifedipine
in six tablets brands. The results obtained as well as that
of the official USP HPLC method are presented in
Table 4. There was found to be no significant difference
in the content of nifedipine in the tablets by both meth-
ods, thereby establishing the equivalence of both
methods.
Relative merits of the new method
The new method described in this work has the advantage
of being relatively simple compared to the official HPLC
method, and it utilises a more readily available instrumen-
tation which can be utilised in any environment for the












Nifedipine 4.35 4.890 103.22 0.037 3.22
8.7 8.857 101.80 2.300 1.801
11.6 11.500 99.12 3.070 −0.008
n= 12, for the 3 days and each concentration levels. RSD, relative standard
deviation.other previously reported spectrophotometric methods,
this new colorimetric method has the advantage of cir-
cumventing extraction with organic solvents which may
compromise accuracy. The method is also relatively simple
as it adopts a two-step process, and it is highly sensitive
compared to previous methods. This new colorimetric
method is the first reported spectrophotometric method
for the analysis of nifedipine based on azo dye formation.
Experimental
Chemicals and reagents
Acetonitrile, ethanol, methanol, 1-propanol, distilled
water, glacial acetic acid, Zinc dust, concentrated HCl
(all analar reagent grade obtained from BDH Chemical
Ltd., Poole, England) and nifedipine reference standard
were utilised in this study.
Nifedipine tablet brands assayed using this new colori-
metric method include the following: Frapine Retard
20 mg/tablet (Medrel Pharmaceutical Ltd.), Nifedin Dexcel
Retard 20 mg/tablet (Dexcel Ltd.), Nifegem Retard 20 mg/
tablet (Gemini Pharmaceuticals Ltd.), Nifecard Retard
20 mg/tablet (Salutas Pharma GmbH), Medipine Retard
20 mg/tablet (Cipla Ltd.) and Nife-D 20 mg/tablet (Lincoln
Pharmaceuticals Ltd.). All the brands were within their
shelf-life periods during analyses.
Equipment
The following equipment were used: analytical balance
(Mettler H80, Mettler-Toledo, Inc., Columbus, OH,
USA), precoated TLC aluminium plate, ultraviolet lamp
254/364 nm (PW Allen and Co., London, UK), digital
colorimeter (Model 6051, Jenway Ltd., Dunmow, Essex
UK), UV-Visible spectrophotometer (PerkinElmer Lamda
25, Cambridge, UK), vortex mixer (Griffin and George
Ltd., Loughborough, UK) and thermostated water bath
(Langford, UK).
Statistical analysis
Statistical analysis was done between the results obtained
from the new colorimetric method and the USP HPLC
assay procedure using Origin version 6.1 (OriginLab
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than or equal to 0.05 were taken as significant using the
variance ratio (F test) and Student's t test.
Conclusions
The new colorimetric method is the first described
method for the analysis of nifedipine by azo dye derivati-
zation methodology. It has low concentrations of calibra-
tion ranges compared to the other existing photometric
methods. There was no interference from common exci-
pients encountered, and it is of equivalent accuracy with
the official USP HPLC method. The method is simple,
highly sensitive, accurate, precise, economical and
suitable for routine analysis of nifedipine in bulk and
drug formulations.
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